SARS-CoV-2 NSP12 Protein Is Not an Interferon-β Antagonist

Author:

Li Aixin1,Zhao Kaitao1ORCID,Zhang Bei1,Hua Rong1,Fang Yujie23,Jiang Wuhui1,Zhang Jing4,Hui Lixia1,Zheng Yingcheng1,Li Yan56,Zhu Chengliang7,Wang Pei-Hui4,Peng Ke2,Xia Yuchen1ORCID

Affiliation:

1. State Key Laboratory of Virology and Hubei Province Key Laboratory of Allergy and Immunology, Institute of Medical Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, China

2. State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China

3. University of Chinese Academy of Sciences, Beijing, China

4. Key Laboratory for Experimental Teratology of Ministry of Education and Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, China

5. Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

6. Tongji-Rongcheng Center for Biomedicine, Huazhong University of Science and Technology, Wuhan, China

7. Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China

Abstract

Previous studies investigated the interaction between SARS-CoV-2 viral proteins and interferon signaling and proposed that several SARS-CoV-2 viral proteins, including NSP12, could suppress IFN-β activation. However, most of these results were generated from IFN-β promoter luciferase reporter assay and have not been validated functionally.

Funder

Hubei Province's Outstanding Medical Academic Leader program

Foundation for Innovative Research Groups of the National Natural Science Foundation of Hubei

Foundation for Innovative Research Groups of Hubei Health Commission

MOE | Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3